Literature DB >> 2543249

Alveolar macrophages from patients with asbestos exposure release increased levels of leukotriene B4.

J G Garcia1, D E Griffith, A B Cohen, K S Callahan.   

Abstract

The alveolar influx and subsequent activation of inflammatory cells such as neutrophils and eosinophils are believed to be important in the pathogenesis of many interstitial lung disorders, including asbestosis. Indices of lower respiratory tract abnormalities detected by bronchoalveolar lavage (BAL) were investigated in 93 asbestos-exposed workers as well as in smoking (n = 12) and nonsmoking (n = 10) control subjects. Patients with clinical asbestosis (n = 12) exhibited increases in both BAL neutrophils and BAL eosinophils, expressed as both percentage of total cells and total numbers, when compared to asbestos-exposed workers without asbestosis (n = 81) and control subjects. Significantly greater numbers of BAL neutrophils were also found in asbestos-exposed workers without asbestosis than in either smoking or nonsmoking control subjects. These abnormalities correlated significantly with in vitro BAL alveolar macrophage production of the potent leukocyte chemotaxin, leukotriene B4 (LTB4). For example, basal, unstimulated LTB4 production was 3.1 +/- 0.8 ng/10(6) alveolar macrophages for patients with asbestosis, 1.05 +/- 0.2 ng/10(6) cells in asbestos workers without asbestosis, 0.9 +/- 0.2 ng/10(6) cells in control nonsmokers, and 0.2 +/- 0.05 ng/10(6) cells in control smokers. Stimulated LTB4 release from BAL alveolar macrophages (A23187 or arachidonate) was even more pronounced in asbestos workers with or without asbestosis, suggesting an in vivo priming effect on alveolar macrophage synthesis of LTB4. Cell-free BAL supernatants from asbestos-exposed patients with or without asbestosis also contained significantly greater amounts of LTB4 than did those from control subjects, indicating enhanced in vivo production of this inflammatory mediator.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543249     DOI: 10.1164/ajrccm/139.6.1494

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  13 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  The molecular basis of asbestos induced lung injury.

Authors:  D W Kamp; S A Weitzman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 3.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Increased alveolar nitric oxide concentration and high levels of leukotriene B(4) and 8-isoprostane in exhaled breath condensate in patients with asbestosis.

Authors:  Hannele Lehtonen; Panu Oksa; Lauri Lehtimäki; Anna Sepponen; Riina Nieminen; Hannu Kankaanranta; Seppo Saarelainen; Ritva Järvenpää; Jukka Uitti; Eeva Moilanen
Journal:  Thorax       Date:  2007-01-24       Impact factor: 9.139

5.  Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis.

Authors:  V De Rose; L Trentin; M T Crivellari; A Cipriani; G Gialdroni Grassi; E Pozzi; G Folco; G Semenzato
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

6.  Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  J Wilborn; M Bailie; M Coffey; M Burdick; R Strieter; M Peters-Golden
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

7.  Elevated interleukin-8 in the alveolitis of individuals with asbestos exposure.

Authors:  M Broser; Y Zhang; C Aston; T Harkin; W N Rom
Journal:  Int Arch Occup Environ Health       Date:  1996       Impact factor: 3.015

Review 8.  Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society.

Authors: 
Journal:  CMAJ       Date:  1992-03-15       Impact factor: 8.262

Review 9.  Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?

Authors:  Steven K Huang; Marc Peters-Golden
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Airflow obstruction in nonsmoking, asbestos- and mixed dust-exposed workers.

Authors:  D E Griffith; J G Garcia; R F Dodson; J L Levin; R S Kronenberg
Journal:  Lung       Date:  1993       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.